Table Graph
      published meta-analysis   sensitivity analysis   studies

remdesivir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 1.37 [0.69; 2.72] 1.37[0.69; 2.72]GS-US-540-5773 (Goldman), 2020 (REV)10%397NAnot evaluable clinical improvementdetailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 1.27 [0.98; 1.63] 1.27[0.98; 1.63]GS-US-540-5773 (Goldman), 2020 (REV)10%397NAnot evaluable clinical improvement (14-day)detailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 0.65 [0.44; 0.98] 0.65[0.44; 0.98]GS-US-540-5773 (Goldman), 2020 (REV)10%397NAnot evaluable clinical improvement (7-day)detailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 0.69 [0.45; 1.05] 0.69[0.45; 1.05]GS-US-540-5773 (Goldman), 2020 (REV)10%397NAnot evaluable clinical improvement (time to event analysis only)detailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 1.27 [0.98; 1.63] 1.27[0.98; 1.63]GS-US-540-5773 (Goldman), 2020 (REV)10%397NAnot evaluable recoverydetailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 1.23 [0.97; 1.57] 1.23[0.97; 1.57]GS-US-540-5773 (Goldman), 2020 (REV)10%397NAnot evaluable serious adverse events (SAE), anydetailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 1.98 [1.27; 3.11] 1.98[1.27; 3.11]GS-US-540-5773 (Goldman), 2020 (REV)10%397NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-04-20 14:25 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 510 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons